# FDA grants EUA to next-gen TaqPath COVID-19 assays

October 2021—Thermo Fisher Scientific announced FDA emergency use authorization of the TaqPath COVID-19 Fast PCR Combo Kit 2.0 and TaqPath COVID-19 RNase P Combo Kit 2.0. Both kits are updated versions of tests, with increased genomic target redundancy to ensure continued accuracy as SARS-CoV-2 mutates.

The TaqPath COVID-19 Fast PCR Combo Kit 2.0 assesses raw saliva and uses a simple workflow from sample collection direct to PCR. Results are available in about two hours. The TaqPath COVID-19 RNase P Combo Kit 2.0 is designed with an approximate three-hour turnaround time and can detect SARS-CoV-2 from individuals suspected of COVID-19 by their health care provider, as well as from patients who are asymptomatic.

*Thermo Fisher Scientific, 781-622-1000*